G. Bruce Papesh Net Worth

The estimated Net Worth of Bruce Papesh is at least $3.16 Milion dollars as of 25 March 2021. Mr. Papesh owns over 7,000 units of Neogen stock worth over $659,730 and over the last 21 years he sold NEOG stock worth over $2,408,562. In addition, he makes $87,376 as Independent Director at Neogen.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Papesh NEOG stock SEC Form 4 insiders trading

G has made over 19 trades of the Neogen stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 7,000 units of NEOG stock worth $436,170 on 25 March 2021.

The largest trade he's ever made was exercising 30,000 units of Neogen stock on 13 January 2021 worth over $839,400. On average, G trades about 3,209 units every 152 days since 2003. As of 25 March 2021 he still owns at least 43,261 units of Neogen stock.

You can see the complete history of Mr. Papesh stock trades at the bottom of the page.

G. Bruce Papesh biography

G. Bruce Papesh serves as Independent Director of the Company. Mr. Papesh was elected to the Board in October 1993 and was the Company’s Secretary from October 1994 to October 1999. Since 1987, Mr. Papesh has served as President of Dart, Papesh & Company, Inc., member of SIPC and FINRA, an investment consulting and financial services firm. Mr. Papesh also served until October 1, 2001 on the board of directors of Immucor, Inc., an immunodiagnostics company that manufactures and markets products for the human clinical blood bank industry. Mr. Papesh has experience in the investment securities industry and in financial analysis which contributes greatly to the Board.

What is the salary of G Papesh?

As the Independent Director of Neogen, the total compensation of G Papesh at Neogen is $87,376. There are 12 executives at Neogen getting paid more, with John Adent having the highest compensation of $2,123,450.

How old is G Papesh?

G Papesh is 73, he's been the Independent Director of Neogen since 1999. There are no older and 13 younger executives at Neogen.

What's G Papesh's mailing address?

Bruce's mailing address filed with the SEC is 726 APPLEGATE LANE, , EAST LANSING, MI, 48823.

Insiders trading at Neogen

Over the last 24 years, insiders at Neogen have traded over $135,917,555 worth of Neogen stock and bought 195,554 units worth $4,379,833 . The most active insiders traders include James L Herbert, Jeffrey D Capello a Lon M Bohannon. On average, Neogen executives and independent directors trade stock every 11 days with the average trade being worth of $140,346. The most recent stock trade was executed by Ronald D Green on 29 August 2024, trading 4,446 units of NEOG stock currently worth $68,780.

What does Neogen do?

neogen corporation develops and markets products dedicated to food and animal safety. the company’s food safety division markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. neogen’s animal safety division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants and rodenticides.

Complete history of Mr. Papesh stock trades at Neogen

Neogen executives and stock owners

Neogen executives and other stock owners filed with the SEC include:

• John Adent,
  President, Chief Executive Officer, Director
• Steven Quinlan,
  Chief Financial Officer, Vice President, Secretary
• John Edward Adent,
  Pres, CEO & Director
• Jason Lilly,
  Vice President - International Business
• Jerome Hagedorn,
  Vice President - Food Safety operations
• Douglas E. Jones,
  VP & Chief Commercial Officer
• Steven J. Quinlan,
  VP & CFO
• James Borel,
  Lead Independent Chairman of the Board
• James Tobin,
  Independent Director
• Ronald Green,
  Independent Director
• William Boehm,
  Independent Director
• Darci Vetter,
  Independent Director
• G. Bruce Papesh,
  Independent Director
• Doug Jones,
  Chief Commercial Officer
• Amy M. Rocklin Ph.D.,
  VP, Gen. Counsel & Corp. Sec.
• Julie A. Mann,
  VP & Chief HR Officer
• Rod Poland,
  Director of Corp. Communications
• Amy Rocklin Ph.D.,
  VP & Gen. Counsel
• Sarah Demey,
  Admin. Mang.
• Bruce Papesh,
  Director
• A Charles Fischer,
  Director
• Richard E Jr Calk,
  President & COO
• Richard T Crowder,
  Director
• Jack C Parnell,
  Director
• Clayton K Yeutter,
  Director
• Thomas H Reed,
  Director
• Terri A Morrical,
  
• David H. Naemura,
  Chief Financial Officer
• Edward Bradley,
  V.P. Sales and Marketing
• Aashima Gupta,
  Director
• Jeffrey D Capello,
  Director
• Rex L Hamilton,
  Vice President
• Herbert D Doan,
  Director
• Gordon E Guyer,
  Director
• James L Herbert,
  Director
• Joseph M Madden,
  V.P. Scientific Affairs
• Richard R Current,
  Vice President & CFO
• Anthony E Maltese,
  VP Business Development
• Kenneth V Kodilla,
  Vice President
• Lon M Bohannon,
  COO
• Mark A Mozola,
  Vice President of R&D
• Leonard E Heller,
  Director
• Robert M Book,
  Director
• Stephen K. Snyder,
  Former Pres. and COO
• Paul S Satoh,
  V.P Research and Development
• Rafael A Rodriguez,
  Director
• Catherine E Woteki,
  Director
• Amy M Rocklin,
  Chief Legal Officer
• John Patrick Moylan,
  Chief Accounting Officer